VYGR
HealthcareVoyager Therapeutics, Inc.
$4.08
+$0.05 (+1.24%)
Jan 5, 2026
Price History (1Y)
Analysis
Voyager Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $226.85 million and 172 employees. The company generates revenue primarily through its operations in the biotechnology industry. Financially, Voyager Therapeutics has reported negative profitability margins, including a gross margin of 0.0%, an operating margin of -228.9%, and a profit margin of 0.0%. Additionally, the company's returns on equity (ROE) and assets (ROA) are also negative at -46.1% and -24.5%, respectively. Voyager Therapeutics has $208.93 million in cash and $38.37 million in debt, resulting in a debt-to-equity ratio of 17.45. Voyager Therapeutics' valuation is influenced by its price-to-book ratio of 1.03 and price-to-sales ratio of 7.24. The company's forward P/E ratio is -2.62, while its revenue growth rate has declined by 45.7% year-over-year.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $226.85M
- P/E Ratio
- N/A
- 52-Week High
- $6.27
- 52-Week Low
- $2.65
- Avg Volume
- 527.71K
- Beta
- 1.28
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 172